STATs profiling reveals predominantly-activated STAT3 in cholangiocarcinoma genesis and progression

Journal of Hepato-Biliary-Pancreatic Sciences

Volumn 21, Issue 10, 2014, Pages 767-776

  Dokduang, Hasaya ^a,b   Techasen, Anchalee ^b   Namwat, Nisana ^a,b   Khuntikeo, Narong ^a,b   Pairojkul, Chawalit ^a,b   Murakami, Yoshinori ^b,c   Loilome, Watcharin ^a,b   Yongvanit, Puangrat ^a  

^a KHON KAEN UNIVERSITY   (Thailand)

^b KHON KAEN UNIVERSITY   (Thailand)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

Cholangiocarcinoma; Inflammation; Signal transducer and activator of transcription 3

Indexed keywords

LIPOPOLYSACCHARIDE; STAT1 PROTEIN; STAT2 PROTEIN; STAT3 PROTEIN; STAT4 PROTEIN; STAT5A PROTEIN; STAT5B PROTEIN; STAT6 PROTEIN; STAT PROTEIN; TUMOR MARKER;

ADULT; AGED; ANIMAL TISSUE; BILE DUCT; BILE DUCT CARCINOMA; CANCER PROGNOSIS; CARCINOGENESIS; CONFERENCE PAPER; DISEASE COURSE; FASCIOLA HEPATICA; FEMALE; HAMSTER; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TISSUE MICROARRAY; TUMOR CELL; ANIMAL; BILE DUCT TUMOR; COMPLICATION; ENZYME IMMUNOASSAY; FASCIOLIASIS; INTRAHEPATIC BILE DUCT; METABOLISM; MIDDLE AGED; MOLECULAR GENETICS; PARASITOLOGY; PATHOLOGY; PHOSPHORYLATION; SURVIVAL RATE; TUMOR CELL CULTURE; WESTERN BLOTTING;

ADULT; AGED; ANIMALS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; BLOTTING, WESTERN; CHOLANGIOCARCINOMA; CRICETINAE; DISEASE PROGRESSION; FASCIOLIASIS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PHOSPHORYLATION; STAT TRANSCRIPTION FACTORS; STAT3 TRANSCRIPTION FACTOR; SURVIVAL RATE; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 84921755552     PISSN: 18686974     EISSN: 18686982     Source Type: Journal    
DOI: 10.1002/jhbp.131     Document Type: Conference Paper

References (48)

1. Elkins DB, Haswell-Elkins MR, Mairiang E, Mairiang P, Sithithaworn P, Kaewkes S, et al. A high frequency of hepatobiliary disease and suspected cholangiocarcinoma associated with heavy Opisthorchis viverrini infection in a small community in north-east Thailand. Trans R Soc Trop Med Hyg. 1990; 84: 715-719.
2. Elkins DB, Mairiang E, Sithithaworn P, Mairiang P, Chaiyakum J, Chamadol N, et al. Cross-sectional patterns of hepatobiliary abnormalities and possible precursor conditions of cholangiocarcinoma associated with Opisthorchis viverrini infection in humans. Am J Trop Med Hyg. 1996; 55: 295-301.
3. Haswell-Elkins MR, Mairiang E, Mairiang P, Chaiyakum J, Chamadol N, Loapaiboon V, et al. Cross-sectional study of Opisthorchis viverrini infection and cholangiocarcinoma in communities within a high-risk area in northeast Thailand. Int J Cancer. 1994; 59: 505-509.
4. Holzinger F, Z'Graggen K, Buchler MW,. Mechanisms of biliary carcinogenesis: a pathogenetic multi-stage cascade towards cholangiocarcinoma. Ann Oncol. 1999; 10 (Suppl 4): 122-126.
5. Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD,. Cholangiocarcinoma. Lancet. 2005; 366: 1303-1314.
6. Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC,. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol. 2002; 37: 806-813.
7. Shaib Y, El-Serag HB,. The epidemiology of cholangiocarcinoma. Semin Liver Dis. 2004; 24: 115-125.
8. Jusakul A, Loilome W, Namwat N, Haigh WG, Kuver R, Dechakhamphu S, et al. Liver fluke-induced hepatic oxysterols stimulate DNA damage and apoptosis in cultured human cholangiocytes. Mutat Res. 2012; 731: 48-57.
9. Pinlaor S, Hiraku Y, Ma N, Yongvanit P, Semba R, Oikawa S, et al. Mechanism of NO-mediated oxidative and nitrative DNA damage in hamsters infected with Opisthorchis viverrini: a model of inflammation-mediated carcinogenesis. Nitric Oxide. 2004; 11: 175-183.
10. Pinlaor S, Yongvanit P, Hiraku Y, Ma N, Semba R, Oikawa S, et al. 8-nitroguanine formation in the liver of hamsters infected with Opisthorchis viverrini. Biochem Biophys Res Commun. 2003; 309: 567-571.
11. Thanan R, Murata M, Pinlaor S, Sithithaworn P, Khuntikeo N, Tangkanakul W, et al. Urinary 8-oxo-7,8-dihydro-2′-deoxyguanosine in patients with parasite infection and effect of antiparasitic drug in relation to cholangiocarcinogenesis. Cancer Epidemiol Biomarkers Prev. 2008; 17: 518-524.
12. Yongvanit P, Pinlaor S, Bartsch H,. Oxidative and nitrative DNA damage: key events in opisthorchiasis-induced carcinogenesis. Parasitol Int. 2012; 61: 130-135.
13. Loilome W, Juntana S, Namwat N, Bhudhisawasdi V, Puapairoj A, Sripa B, et al. PRKAR1A is overexpressed and represents a possible therapeutic target in human cholangiocarcinoma. Int J Cancer. 2011; 129: 34-44.
14. Loilome W, Yongvanit P, Wongkham C, Tepsiri N, Sripa B, Sithithaworn P, et al. Altered gene expression in Opisthorchis viverrini-associated cholangiocarcinoma in hamster model. Mol Carcinog. 2006; 45: 279-287.
15. Techasen A, Loilome W, Namwat N, Takahashi E, Sugihara E, Puapairoj A, et al. Myristoylated alanine-rich C kinase substrate phosphorylation promotes cholangiocarcinoma cell migration and metastasis via the protein kinase C-dependent pathway. Cancer Sci. 2010; 101: 658-665.
16. Dokduang H, Juntana S, Techasen A, Namwat N, Yongvanit P, Khuntikeo N, et al. Survey of activated kinase proteins reveals potential targets for cholangiocarcinoma treatment. Tumour Biol. 2013; 34: 3519-3528.
17. Bromberg J, Darnell JE, Jr,. The role of STATs in transcriptional control and their impact on cellular function. Oncogene. 2000; 19: 2468-2473.
18. Hoey T, Schindler U,. STAT structure and function in signaling. Curr Opin Genet Dev. 1998; 8: 582-587.
19. Horvath CM,. STAT proteins and transcriptional responses to extracellular signals. Trends Biochem Sci. 2000; 25: 496-502.
20. Bromberg J,. Stat proteins and oncogenesis. J Clin Invest. 2002; 109: 1139-1142.
21. Smirnova OV, Ostroukhova TY, Bogorad RL,. JAK-STAT pathway in carcinogenesis: is it relevant to cholangiocarcinoma progression? World J Gastroenterol. 2007; 13: 6478-6491.
22. Turkson J, Jove R,. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene. 2000; 19: 6613-6626.
23. Techasen A, Loilome W, Namwat N, Dokduang H, Jongthawin J, Yongvanit P,. Cytokines released from activated human macrophages induce epithelial mesenchymal transition markers of cholangiocarcinoma cells. Asian Pac J Cancer Prev. 2012; 13 (Suppl): 115-118.
24. Chan-On W, Nairismagi ML, Ong CK, Lim WK, Dima S, Pairojkul C, et al. Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat Genet. 2013; 45: 1474-1478.
25. Sugimachi K, Taguchi K, Aishima S, Tanaka S, Shimada M, Kajiyama K, et al. Altered expression of beta-catenin without genetic mutation in intrahepatic cholangiocarcinoma. Mod Pathol. 2001; 14: 900-905.
26. Aljiffry M, Walsh MJ, Molinari M,. Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009. World J Gastroenterol. 2009; 15: 4240-4262.
27. Li C, Wang Z, Liu Y, Wang P, Zhang R,. STAT3 expression correlates with prognosis of thymic epithelial tumors. J Cardiothorac Surg. 2013; 8: 92-98.
28. Songserm N, Promthet S, Sithithaworn P, Pientong C, Ekalaksananan T, Chopjitt P, et al. Risk factors for cholangiocarcinoma in high-risk area of Thailand: role of lifestyle, diet and methylenetetrahydrofolate reductase polymorphisms. Cancer Epidemiol. 2012; 36: e89-94.
29. Mandell JW,. Immunohistochemical assessment of protein phosphorylation state: the dream and the reality. Histochem Cell Biol. 2008; 130: 465-471.
30. Bingle L, Brown NJ, Lewis CE,. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol. 2002; 196: 254-265.
31. Subimerb C, Pinlaor S, Khuntikeo N, Leelayuwat C, Morris A, McGrath MS, et al. Tissue invasive macrophage density is correlated with prognosis in cholangiocarcinoma. Mol Med Rep. 2010; 3: 597-605.
32. Matsumura I, Kitamura T, Wakao H, Tanaka H, Hashimoto K, Albanese C, et al. Transcriptional regulation of the cyclin D1 promoter by STAT5: its involvement in cytokine-dependent growth of hematopoietic cells. EMBO J. 1999; 18: 1367-1377.
33. Yu H, Pardoll D, Jove R,. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009; 9: 798-809.
34. Leung S, Qureshi SA, Kerr IM, Darnell JE, Jr, Stark GR,. Role of STAT2 in the alpha interferon signaling pathway. Mol Cell Biol. 1995; 15: 1312-1317.
35. Sironi JJ, Ouchi T,. STAT1-induced apoptosis is mediated by caspases 2, 3, and 7. J Biol Chem. 2004; 279: 4066-4074.
36. Bruns HA, Kaplan MH,. The role of constitutively active Stat6 in leukemia and lymphoma. Crit Rev Oncol Hematol. 2006; 57: 245-253.
37. Lin TS, Mahajan S, Frank DA,. STAT signaling in the pathogenesis and treatment of leukemias. Oncogene. 2000; 19: 2496-2504.
38. Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S, et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med. 2004; 10: 48-54.
39. Takeda K, Akira S,. STAT family of transcription factors in cytokine-mediated biological responses. Cytokine Growth Factor Rev. 2000; 11: 199-207.
40. Cao X, Tay A, Guy GR, Tan YH,. Activation and association of Stat3 with Src in v-Src-transformed cell lines. Mol Cell Biol. 1996; 16: 1595-1603.
41. Turkson J, Bowman T, Garcia R, Caldenhoven E, De Groot RP, Jove R,. Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol Cell Biol. 1998; 18: 2545-2552.
42. Isomoto H, Kobayashi S, Werneburg NW, Bronk SF, Guicciardi ME, Frank DA, et al. Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. Hepatology. 2005; 42: 1329-1338.
43. Isomoto H, Mott JL, Kobayashi S, Werneburg NW, Bronk SF, Haan S, et al. Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing. Gastroenterology. 2007; 132: 384-396.
44. Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J, Tabak B, et al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology. 2013; 144: 829-840.
45. Sia D, Tovar V, Moeini A, Llovet JM,. Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies. Oncogene. 2013; 32: 4861-4870.
46. Senggunprai L, Kukongviriyapan V, Prawan A, Kukongviriyapan U,. Quercetin and EGCG exhibit chemopreventive effects in cholangiocarcinoma cells via suppression of JAK/STAT signaling pathway. Phytother Res. 2014; 28: 841-848.
47. Sripa B, Mairiang E, Thinkhamrop B, Laha T, Kaewkes S, Sithithaworn P, et al. Advanced periductal fibrosis from infection with the carcinogenic human liver fluke Opisthorchis viverrini correlates with elevated levels of interleukin-6. Hepatology. 2009; 50: 1273-1281.
48. Sripa B, Thinkhamrop B, Mairiang E, Laha T, Kaewkes S, Sithithaworn P, et al. Elevated plasma IL-6 associates with increased risk of advanced fibrosis and cholangiocarcinoma in individuals infected by Opisthorchis viverrini. PLoS Negl Trop Dis. 2012; 6: e1654.